Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
10 Jan 2022
10 Jan 2022
Historique:
received:
15
06
2021
accepted:
06
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
The crosstalk between estrogen and HER2 receptors and cell-cycle regulation sustains resistance to endocrine therapy of HER2- and hormone receptor-positive breast cancer. We earlier reported that women with HER2 and ER-positive breast cancer receiving neoadjuvant dual HER2-block and palbociclib in the NA-PHER2 trial had Ki67 decrease and 27% pathological complete responses (pCR). We extended NA-PHER2 to Cohort B using dual HER2-block and palbociclib without fulvestrant and report here Ki67 drops at week-2 (mean change -25.7), at surgery (after 16 weeks, mean change -9.5), high objective response (88.5%) and pCR (19.2%). In Cohort C [Ki67 > 20% and HER2
Identifiants
pubmed: 35013314
doi: 10.1038/s41523-021-00377-8
pii: 10.1038/s41523-021-00377-8
pmc: PMC8748500
doi:
Banques de données
ClinicalTrials.gov
['NCT02530424']
Types de publication
Journal Article
Langues
eng
Pagination
1Informations de copyright
© 2022. The Author(s).
Références
Cancer Cell. 2018 Jul 9;34(1):9-20
pubmed: 29731395
Endocr Rev. 2008 Apr;29(2):217-33
pubmed: 18216219
Clin Cancer Res. 2017 Aug 1;23(15):4055-4065
pubmed: 28270497
Annu Rev Med. 2011;62:233-47
pubmed: 20887199
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
Lancet. 2012 Feb 18;379(9816):633-40
pubmed: 22257673
Lancet Oncol. 2018 Feb;19(2):249-256
pubmed: 29326029
Breast Cancer Res. 2016 Jun 28;18(1):67
pubmed: 27349747
Lancet Oncol. 2020 Nov;21(11):1443-1454
pubmed: 33152284
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8
pubmed: 18812550
Clin Cancer Res. 2015 Sep 1;21(17):3995-4003
pubmed: 26015514
Ann Oncol. 2013 Sep;24(9):2278-84
pubmed: 23704196
J Clin Pathol. 2013 Jun;66(6):512-6
pubmed: 23436927
Ann Oncol. 2019 Jun 1;30(6):921-926
pubmed: 30778520
Mol Cell Biol. 1996 Dec;16(12):6917-25
pubmed: 8943347
Br J Cancer. 1999 Mar;79(7-8):1220-6
pubmed: 10098763
Nat Clin Pract Oncol. 2008 Sep;5(9):531-42
pubmed: 18607391
JAMA Oncol. 2018 Mar 1;4(3):302-308
pubmed: 29327055
J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):169-74
pubmed: 9699870
Clin Cancer Res. 2020 Feb 1;26(3):566-580
pubmed: 31615937
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Biochem Soc Trans. 2010 Feb;38(Pt 1):217-22
pubmed: 20074063